Indaptus Therapeutics Presents New Cohort Data Confirming Original "Pulse-Prime" Hypothesis Via Phase 1 Clinical Trial Of Decoy20 At The ASCO Annual Meeting

5/29/24 8:27:37 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $INDP alert in real time by email

Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces data from a poster being presented at the American Society of Clinical Oncology Annual Meeting 2024 on June 1. The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented.

Get the next $INDP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INDP

Date	Price Target	Rating	Analyst
1/31/2022	$15.00	Buy	HC Wainwright & Co.
10/19/2021	$16.00	Hold → Buy	Maxim Group

More analyst ratings

$INDP
Press Releases

Fastest customizable press release news feed in the world

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, "The recent announcement highlighting our clinical supply agreement with BeiGene is an important milestone, representing a significant step forward in our clinical development as we plan the first clinical trial combining BeiGene's anti-PD-1 antibody, tislelizumab, with Indap
11/12/24 8:00:00 AM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today that Dr. Michael Newman, Founder and Chief Scientific Officer, has published his groundbreaking research in the peer-reviewed journal, Frontiers in Immunology. The article, titled "Invention and Characterization of a Systemically Administered, Attenuated and Killed Bacteria-Based Multiple Immune Receptor Agonist for Antitumor Immunotherapy," presents the Company's innovative approach to activating both the innate and adaptive sides of the immune sy
11/11/24 8:00:00 AM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial. The SITC conference is being held November 6-10, 2024 in Houston, Tex. The data presented demonstrated that D
11/7/24 8:00:00 AM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care

$INDP
Leadership Updates

Live Leadership Updates

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn. Indaptus Therapeutics emerges from over a century of groundbreaking advancements in immunotherapy and has built an approach that is designed to stimulate a broad acting effect on the immune sy
2/8/24 8:00:00 AM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. "We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors. As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first cohort patients have maintained stable disease since receiving their single dose and presented evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mech
11/6/23 4:01:00 PM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. "We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced, we are pleased to observe evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mechanism of action," said Jeffrey Meckler, Chief Executive Officer of Indapt
8/14/23 8:00:00 AM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus' broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 Indaptus Therapeutics Management will hold a conference call on October 22, 2024 at 4:30PM ET to discuss the agreement and future plans NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced a clinical supply agreement with BeiGene. Building on Indaptus' preclinical observation that Decoy20, when combined with a PD-1 inhibitor, induced complete
10/22/24 8:00:00 AM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care
Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), today announces financial results for the third quarter ended September 30, 2022 and provides a corporate update. "We continue to diligently prepare for the launch of our Phase 1 trial of Decoy20 for the treatment of solid tumors, while carefully managing our expenses," said Jeffrey Meckler, chief executive officer of Indaptus. "Once we have finalized the initiation process with our trial sites we will be prepared to speak more openly about progress, including tr
11/10/22 4:05:00 PM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care
Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), today announces financial results for the second quarter ended June 30, 2022 and provides a corporate update. "We made substantial progress throughout the second quarter, highlighted by the FDA clearance of our IND application for systemically administered Decoy20. This important regulatory milestone keeps us on track to initiate our first in human clinical trial this year," said
8/8/22 8:00:00 AM ET
$INDP
Biotechnology: Pharmaceutical Preparations
Health Care

Indaptus Therapeutics Presents New Cohort Data Confirming Original "Pulse-Prime" Hypothesis Via Phase 1 Clinical Trial Of Decoy20 At The ASCO Annual Meeting

Chat with this insight

Recent Analyst Ratings for $INDP

$INDP SEC Filings

Indaptus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Indaptus Therapeutics Inc. filed SEC Form 8-K: Other Events

Amendment: SEC Form D/A filed by Indaptus Therapeutics Inc.

$INDP Press Releases

Fastest customizable press release news feed in the world

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

$INDP Large Ownership Changes

This live feed shows all institutional transactions in real time.

$INDP Market Insights

Live Market Insights

SEC Form SC 13D filed by Indaptus Therapeutics Inc.

SEC Form SC 13G/A filed by Indaptus Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Indaptus Therapeutics Inc. (Amendment)

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

Indaptus Therapeutics To Present At STING & TLR-Targeted Therapies Summit Jun. 19-20

12 Health Care Stocks Moving In Friday's Pre-Market Session

$INDP Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. resumed coverage on Indaptus Therapeutics with a new price target

Indaptus Therapeutics upgraded by Maxim Group with a new price target

$INDP Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by CEO and Director Meckler Jeffrey A

SEC Form 4 filed by Chief Operating Officer Linscott Walt Addison

SEC Form 4 filed by CSO and Director Newman Michael James

$INDP Leadership Updates

Live Leadership Updates

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

$INDP Financials

Live finance-specific insights

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Recent Analyst Ratings for
$INDP

$INDP
SEC Filings

$INDP
Press Releases

$INDP
Large Ownership Changes

$INDP
Market Insights

$INDP
Analyst Ratings

$INDP
Insider Trading

$INDP
Leadership Updates

$INDP
Financials